Showing 2381-2390 of 5909 results for "".
- Myra Vision Announces First-in-Human Use of its Calibreye Glaucoma Drainage Devicehttps://modernod.com/news/myra-vision-announces-first-in-human-use-of-its-calibreye-glaucoma-drainage-device/2481816/Myra Vision announced it has initiated its first-in-human clinical study of the Calibreye System, a glaucoma drainage device with titratable outflow control designed to achieve optimal reduction of IOP for moderate to severe glaucoma patients. The prospective, non-randomized open-label
- DigitalOptometrics to Demonstrate Its Remote Comprehensive Exam Services With Instant Language Translation Capabilities at Vision Expo Westhttps://modernod.com/news/digitaloptometrics-to-demonstrate-its-remote-comprehensive-exam-services-with-instant-language-translation-capabilities-at-vision-expo-west/2481811/DigitalOptometrics, a provider of remote comprehensive eye exam services, will demonstrate its technology at Vision Expo West, September 28-30. Attendees can interact with a remote optometrist in real-time and experience a patient-centric comprehensive eye exam conducted via high-definition
- SightGlass Vision Reports 4-Year Clinical Trial Outcomes for Myopia Control DOT Spectacle Lenseshttps://modernod.com/news/sightglass-vision-reports-4-year-clinical-trial-outcomes-for-myopia-control-dot-spectacle-lenses/2481810/SightGlass Vision reported positive 4-year outcomes from its pivotal CYPRESS study extension, which is evaluating the myopia control performance of the company’s Diffusion Optics Technology (DOT 0.2) spectacle lenses. The lenses use thousands of light scattering el
- UC Irvine Researchers Discover a Nanobody that May Lead to Treatment for Retinitis Pigmentosahttps://modernod.com/news/uc-irvine-researchers-discover-a-nanobody-which-may-lead-to-treatment-for-retinitis-pigmentosa/2481805/A team of scientists from the University of California, Irvine, believe they have discovered a special antibody which may lead to a treatment for retinitis pigmentosa. The study,
- Tarsus Launches Demodex Blepharitis Treatment Xdemvyhttps://modernod.com/news/tarsis-launches-demodex-blepharitis-treatment-xdemvy/2481792/Tarsus Pharmaceuticals announced that Xdemvy (lotilaner ophthalmic solution 0.25%) is now available at pharmacies nationwide for prescription. The FDA approved Xdemvy on July 24, 2023, for the treatment of Demodex blepharitis. “We are delighted that w
- Penn Medicine Neuroscientists Identify Brain Mechanism that Drives Focus Despite Distractionshttps://modernod.com/news/penn-medicine-neuroscientists-identify-brain-mechanism-that-drives-focus-despite-distractions/2481770/In a new study published in Neuron, neuroscientists in the Perelman School of Medicine at the University of Pennsylvania sought to illuminate the neural mechanism that helps the brain decide whether to focus visual
- Kodiak Discontinues Further Development of Tarcocimab After Phase 3 Trial Datahttps://modernod.com/news/kodiak-discontinues-further-development-of-tarcocimab-after-phase-3-trial-data/2481748/Kodiak Sciences has announed it discontinuing further development of tarcocimab tedromer, a novel antibody biopolymer conjugate, being evaluated for wet AMD and DME. The decision comes after the GLEAM and GLIMMER studies failed to meet their primary efficacy endpoints. Th
- FDA Approves Xdemvy, First Treatment for Demodex Blepharitishttps://modernod.com/news/fda-approves-xdemvy-first-treatment-for-demodex-blepharitis/2481743/The FDA has approved Tarsus Pharmaceuticals' Xdemvy (lotilaner ophthalmic solution 0.25%) for the treatment of Demodex blepharitis. Xdemvy, formerly known as TP-03, is the first and only FDA approved treatment to directly target Demodex mites, the root cause
- FDA Accepts DORC’s Orphan-Drug Designation Application for Trypan Blue and Brilliant Blue Ghttps://modernod.com/news/fda-accepts-dorcs-orphan-drug-designation-application-for-trypan-blue-and-brilliant-blue-g/2481740/DORC has has received notification from the FDA that their application for orphan drug designation for a dual combination of Trypan Blue and Brilliant Blue G ophthalmic solutions has been granted. DORC's MembraneBlue-Dual ILM and ERM stain has been used in more than 500,00
- RestoringVision Appoints of Three Directors to its Leadership Teamhttps://modernod.com/news/restoringvision-appoints-of-three-directors-to-its-leadership-team/2481739/Nonprofit RestoringVision announced the appointment of three directors to its leadership team to strengthen its impact in solving the global vision crisis. This follows a year of growth, in which RestoringVision expanded its reach by 48 percent in 2022. In 2023, the organization aims to reac